Assessing Guardant Health (GH) Valuation After A Strong Share Price Run

Event context and recent stock performance

Guardant Health (GH) has drawn investor attention after recent trading, with the stock closing at US$118.95 and showing gains over the past month and past 3 months.

See our latest analysis for Guardant Health.

The recent move to US$118.95 follows a strong run, with a 7 day share price return of 25.32% and a 1 year total shareholder return of 213.03%, suggesting momentum has been building rather than fading.

If Guardant Health’s surge has you thinking about what else is moving in healthcare AI, it is worth scanning 34 healthcare AI stocks

After a move this strong, the real question is whether Guardant Health’s current US$118.95 price and recent gains already capture its growth story, or if the current valuation still leaves room for a buying opportunity that markets have not fully priced in.

Most Popular Narrative: 7.3% Undervalued

Guardant Health’s most followed valuation narrative puts fair value at $128.33, a little above the latest $118.95 close, framing the recent surge as still short of that mark.

Substantial regulatory, reimbursement, and clinical validation milestones (including Shield’s breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.

Read the complete narrative.

Want to see what that kind of adoption could mean for Guardant Health’s revenue and earnings profile? The narrative describes ambitious growth, margin improvement, and a rich future earnings multiple as the elements intended to connect today’s losses with tomorrow’s valuation case.

Result: Fair Value of $128.33 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the bullish story can quickly wobble if high R&D and Shield spending keep cash burn elevated, or if payer adoption and reimbursement for key tests prove slower than expected.

Find out about the key risks to this Guardant Health narrative.

Another View on Guardant Health’s Valuation

The Simply Wall St DCF model presents a very different perspective, with an estimated future cash flow value of $209.53 per share compared to the current $118.95 price. That gap suggests the analyst narrative might still be conservative. Which set of assumptions do you find more realistic?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

All this mixed sentiment around Guardant Health’s momentum, valuation, and future cash flows makes it worth reviewing the data directly and deciding where you stand based on the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Guardant Health has caught your eye, do not stop here. The right watchlist of fresh ideas can be just as important as any single stock pick.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com